Dramatic multifocal osteosarcoma treatment response in the setting of POT1 tumor predisposition syndrome
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Aug 2025 · 1 min read
In brief
In brief
This case report describes a 15-year-old male with POT1 tumor predisposition syndrome who developed synchronous multifocal osteosarcoma—typically associated with poor prognosis—but achieved long-term remission following standard chemotherapy. The dramatic treatment response may represent a unique chemosensitive phenotype in POT1-related osteosarcoma.
Written by the GCMD Library team from the article.
Statements in this article
POT1 tumor predisposition is associated with a spectrum of malignancies due to loss of function mutations in POT1 leading to telomere elongation and genomic instability.
Osteosarcoma is the most common primary malignant bone tumor and has a poor prognosis when multifocal.
A POT1 splice site variant (c.949+1G>C) identified both somatically and in the germline is consistent with POT1 tumor predisposition syndrome.
Multifocal osteosarcoma with POT1 tumor predisposition syndrome displayed marked chemosensitivity to standard of care therapy and long-term remission was achieved.
Hereditable alterations in telomeric function including POT1 are enriched in sarcoma susceptibility.
Hereditary tumor predisposition syndromes often increase osteosarcoma risk.
Five patients with POT1 tumor predisposition syndrome have been reported with osteosarcoma.
Multifocal osteosarcoma is rare and retrospective cohorts suggest dismal prognosis.
Synchronous multifocal osteosarcoma exquisitely sensitive to chemotherapy may represent a unique phenotype for POT1 tumor predisposition syndrome.